 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- TRS01 / Tarsius Pharma
Dazdotuftide: A New Steroid-Free Treatment for Noninfectious Anterior Uveitis With a Superior IOP Safety Profile (POSTER THEATER) - Sep 24, 2024 - Abstract #AAO2024AAO_659;
Further, among subjects who reached ACC = 0 at Day 28, TRS01-treated subjects benefited from statistically significantly improved outcomes for each IOP endpoint (including change from baseline and at each IOP threshold evaluated [P < .05]) versus steroid-treated subjects. Conclusion TRS01 offers the potential to serve as an effective and safe treatment in uveitis that meets the urgent need for a drug that resolves inflammation without the associated risks of IOP elevation and glaucoma.
- ||||| TRS01 / Tarsius Pharma
Trial completion: A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - Aug 28, 2023
P3, N=142, Completed, Sponsor: Tarsier Pharma
Conclusion TRS01 offers the potential to serve as an effective and safe treatment in uveitis that meets the urgent need for a drug that resolves inflammation without the associated risks of IOP elevation and glaucoma. Active, not recruiting --> Completed
- |||| TRS01 / Tarsius Pharma
Enrollment closed: A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - Apr 18, 2023
P3, N=162, Active, not recruiting, Sponsor: Tarsier Pharma
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| TRS01 / Tarsius Pharma
Trial completion date, Trial primary completion date: A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - Nov 1, 2022
P3, N=162, Recruiting, Sponsor: Tarsier Pharma
Recruiting --> Active, not recruiting Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Jan 2023 --> Apr 2023
- || TRS01 / Tarsius Pharma
Trst01 and Rubix Partner to Accelerate Climate Action Through Green Blockchain Platforms https://t.co/GS5Nn2ZOv0 (Twitter) - May 3, 2022
- TRS01 / Tarsius Pharma
TRS01, a Novel Nonsteroidal Treatment of Active Noninfectious Anterior Uveitis: Results of a Phase 1/2 clinical trial (Morial Convention Center) - Oct 20, 2021 - Abstract #AAO2021AAO_1718;
71.4% of subjects in the 1% group reached zero cells on Week 3 and 4. Conclusion Results indicate preliminary safety and efficacy of TRS01 in resolution of anterior uveitis, to be confirmed in Phase 3 trials.
- |||| TRS01 / Tarsius Pharma
Enrollment open: A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - Sep 20, 2021
P3, N=162, Recruiting, Sponsor: Tarsier Pharma
Conclusion Results indicate preliminary safety and efficacy of TRS01 in resolution of anterior uveitis, to be confirmed in Phase 3 trials. Not yet recruiting --> Recruiting
- |||||||| TRS01 / Tarsius Pharma
New P3 trial: A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma (clinicaltrials.gov) - Sep 12, 2021
P3, N=162, Not yet recruiting, Sponsor: Tarsier Pharma
- ||| TRS01 / Tarsius Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis (clinicaltrials.gov) - Feb 3, 2021
P1/2, N=16, Completed, Sponsor: Tarsius Pharma
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=10 --> 16 | Trial completion date: Feb 2021 --> Aug 2020 | Trial primary completion date: Feb 2021 --> Aug 2020
- ||| TRS01 / Tarsius Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study of TRS01 in Participants With Post-surgical Ocular Inflammation (clinicaltrials.gov) - Feb 3, 2021
P1/2, N=37, Completed, Sponsor: Tarsius Pharma
Active, not recruiting --> Completed | N=10 --> 16 | Trial completion date: Feb 2021 --> Aug 2020 | Trial primary completion date: Feb 2021 --> Aug 2020 Active, not recruiting --> Completed | N=60 --> 37 | Trial completion date: Feb 2021 --> Jul 2020 | Trial primary completion date: Feb 2021 --> Jul 2020
- TRS01 / Tarsius Pharma
Enrollment closed: A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis (clinicaltrials.gov) - Aug 10, 2020
P1/2, N=10, Active, not recruiting, Sponsor: Tarsius Pharma
Active, not recruiting --> Completed | N=60 --> 37 | Trial completion date: Feb 2021 --> Jul 2020 | Trial primary completion date: Feb 2021 --> Jul 2020 Recruiting --> Active, not recruiting
- || TRS01 / Tarsius Pharma
Enrollment closed: A Study of TRS01 in Participants With Post-surgical Ocular Inflammation (clinicaltrials.gov) - Aug 10, 2020
P1/2, N=60, Active, not recruiting, Sponsor: Tarsius Pharma
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- TRS01 / Tarsius Pharma
Enrollment open: A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis (clinicaltrials.gov) - Feb 6, 2020
P1/2, N=10, Recruiting, Sponsor: Tarsius Pharma
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| TRS01 / Tarsius Pharma
Enrollment open: A Study of TRS01 in Participants With Post-surgical Ocular Inflammation (clinicaltrials.gov) - Feb 6, 2020
P1/2, N=60, Recruiting, Sponsor: Tarsius Pharma
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | TRS01 / Tarsius Pharma
New P1/2 trial: A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis (clinicaltrials.gov) - Jan 8, 2020
P1/2, N=10, Not yet recruiting, Sponsor: Tarsius Pharma
- | TRS01 / Tarsius Pharma
New P1/2 trial: A Study of TRS01 in Participants With Post-surgical Ocular Inflammation (clinicaltrials.gov) - Jan 8, 2020
P1/2, N=60, Not yet recruiting, Sponsor: Tarsius Pharma